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Background: A major immune evasion mechanism of HIV-1 is the accumulation of non-synonymous mutations in
and around T cell epitopes, resulting in loss of T cell recognition and virus escape.
Results: Here we analyze primary CD8+ T cell responses and virus escape in a HLA B*81 expressing subject who
was infected with two T/F viruses from a single donor. In addition to classic escape through non-synonymous
mutation/s, we also observed rapid selection of multiple recombinant viruses that conferred escape from T cells
specific for two epitopes in Nef.
Conclusions: Our study shows that recombination between multiple T/F viruses provide greater options for acute
escape from CD8+ T cell responses than seen in cases of single T/F virus infection. This process may contribute to
the rapid disease progression in patients infected by multiple T/F viruses.
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HIV-1 specific CD8+ T cells are first detected prior to
peak viremia and expand concomitantly with decline of
acute plasma virus load (pVL) [1,2]. HIV-1 peptide epi-
topes are presented to CD8+ T cells in complex with poly-
morphic human leukocyte antigen (HLA)-I molecules.
Certain HLA allotypes are associated with lower pVL set-
points and better clinical outcomes, suggesting an import-
ant role for CD8+ T cells in control of HIV-1 replication
[3-6]. HIV-1 specific CD8+ T cells are also a major select-
ive force in viral evolution in vivo [7,8] and can select
non-synonymous virus escape mutants in and around the
reactive epitope, that wholly or partially ablate T cell re-
activity, within weeks of infection [9,10]. The timing of
escape for each epitope is not random and is heavily im-
pacted by the relative immunodominance of an individual
CD8+ T cell response and the Shannon entropy, or popu-
lation variability, of the targeted epitope [10,11].
HIV-1 infection with a single transmitted/founder (T/F)
virus occurs in around 80% of heterosexual infections* Correspondence: fgao@duke.edu; nilu_goonetilleke@med.unc.edu
2Department of Medicine, Duke University, Durham, NC 27710, USA
8Department of Microbiology & Immunology, University of North Carolina at
Chapel Hill, Chapel Hill, NC 27599, USA
Full list of author information is available at the end of the article
© 2014 Ritchie et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[12-14]. The proportion of multiple T/F viruses initiating
infection increases in other groups, such as men who have
sex with men and intravenous drug users. Infection with
multiple T/F viruses is linked to factors that are known to
increase overall transmission rates, such as higher risk sex
acts and other concurrent sexually transmitted infections
[12,15-19]. Several studies have associated infection with
multiple HIV-1 T/F viruses, multiple subtypes, and/or a
diverse virus population, with higher pVL setpoint, faster
CD4+ T cell decline, earlier need for anti-retroviral ther-
apy and a worse prognosis for the infected individual
[14,20-24].
The emergence of recombinant viruses results from in-
fection of a cell with two or more different viruses [25].
HIV-1 is highly recombinogenic [26] and HIV-1 recombin-
ation has been observed in patients infected with multiple
viruses within weeks-months of infection [12,14,15,17]. Al-
though none of these acute-phase studies have experimen-
tally linked the emergence of recombinants to immune
responses, several mathematical models have suggested that
recombination may impact escape from CD8+ T cell re-
sponses [27,28]. Such associations have been suggested in
one study of superinfection during the chronic stage of
HIV-1 infection [29].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ruses. We find that differential T cell targeting of the two
T/F viruses drives accelerated recombination-mediated es-
cape in acute infection.
Results
Acute HIV-1 replication in subject CH078
Subject CH078 was detected in acute HIV-1 infection
stage Fiebig I/II (seronegative, pVL= 3 748 087 copies/ml),
near peak viremia [30,31]. Genital ulcer disease, which has
been associated with higher risk of HIV-1 transmission
[32], was diagnosed at enrolment, 3 weeks later. From
peak viremia, his pVL declined rapidly by ~2 log within
the first 28 days from Fiebig I-II, then stabilized, even in-
creasing slightly over the next 7 weeks (days 28–77). This
was followed by a period of slower pVL decline of ~1 log
over several months to establish a setpoint of 3,520 cop-
ies/ml around 6 months post-screening (Figure 1). CD4+
cell counts increased from a nadir of 251 cells/μl, 21 days
post-screening and remained >300 cells/μl over the rest of
the study period (441 days total) (Figure 1). His HLA type
(A*01, A*30, B*42, B*81, Cw*17, Cw*18) included the pro-
tective HLA B*81 allele. In accordance with local clin-
ical practice guidelines applicable at the time, he was
not initiated on antiretroviral therapy during the course
of this study.
Patient CH078 was infected with two T/F viruses
Single genome amplification (SGA) and sequencing of
overlapping 5′ and 3′ halves of HIV-1 genomes from sub-
ject plasma were performed at nine time points from
screening to 441 days post-screening (Figure 1). ThisFigure 1 Clinical data and experimental protocol for patient CH078. C
screening. The plasma VL (red points and black line) and CD4+ T cell coun
within the first 28 days from screening. Next pVL stabilized from days 28–7
several months to establish a setpoint of 3,520 copies/ml around 6 months p
T cell ELISpot (purple arrows), and flow cytometry (green arrows) at the timepapproach [13], allowed for analysis of recombination
events. Fifty, 3′-half genome sequences were analyzed at
screening (Fiebig I-II) giving > 90% confidence to detect
virus variants at the 5% level [12]. Analysis identified
(Additional file 1: Figure S1), a ‘major’ (96%) predominat-
ing virus with the other T/F ‘minor’ accounting for the re-
mainder of the viral populations. These viruses were
highly related (1.2% nucleotide differences in env) suggest-
ing transmission from a single donor. The greatest vari-
ability was observed in Nef which differed by 10.7% at the
amino acid (aa) level (Table 1). Two viral lineages were
also detected in the 5′ side of the virus; however the pre-
sumed minor population (2 of 11 sequences) was not de-
tected until 28 days post-screening (Additional file 1:
Figure S1). Therefore, the 5′ half of the genome sequence
for the minor T/F virus could not be reliably inferred and
differences between the major and minor T/F viruses in
the 3′ half genome were used to track changes in relative
viral frequencies and recombination.
The first recombinant viruses were detected at day 35
from Fiebig I/II, as pVL initially stabilized (day 28–77).
Recombinants then rapidly increased in frequency, reach-
ing 44% of all sequences at day 42 and representing 100%
of all sequences at day 77 and all subsequent timepoints
(Additional file 1: Figure S1).
Primary HIV-1 specific CD8+ T cell responses target
both viruses
We examined whether acute T cell responses were asso-
ciated with virus escape by mutation and recombination.
HIV-1 specific T cell responses were comprehensively
mapped in IFN-γ ELISpot assays using overlappingH078 was HIV-1 viral RNA positive, antibody negative (Fiebig I/II) at
ts (blue points and line) are shown. pVL declined rapidly by ~2 log
7, followed by another period of slower pVL decline of ~1 log over
ost-screening. Samples were used for SGA sequencing (orange arrows),
oints indicated.
Table 1 The sequence differences between the two T/F
viruses in CH078 for each gene in the 3′ half viral genome
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minor T/F viruses, and optimal epitopes subsequently de-
fined experimentally. All T cell responses were CD8+ re-
stricted and dominated by a central memory CD45RO +
CD27+ phenotype (Additional file 2: Figure S2).
Five primary HIV-1 specific T cell responses were de-
tected when pVL was rapidly declining in acute infection
(Figures 1 and 2A) of which four (Gag180-188, Pol426-
434, Vif73-81, Rev12-20) targeted identical epitopes in the
major and minor viruses (shared epitopes). Variable escape
kinetics were observed following the accumulation ofFigure 2 High frequency HIV-1 specific T cell responses were induced
on PBMCs from CH078 between 21 and 442 days post-screening (Fiebig I/I
plotted as absolute magnitude (A) or % of total magnitude (B). The plasm
A T cell response was considered positive if it was ≥30 SFU/106 cells and ≥
spot forming units (SFU) per million PBMCs. For each response the epitope
proteins, the experimentally confirmed sequence, HLA restriction and epito
types indicate the HLA type predicted for the epitope based on binding mnon-synonymous mutations within the targeted epitopes
(Figure 3). The fifth T cell response targeted a 9-mer epi-
tope (Nef68-76) that varied between the two T/F viruses
by 1 aa at position 71 (variable epitope).
As infection progressed, three new HIV-1 specific T cell
responses emerged, two targeting shared epitopes (Gag25-
34, Env209-217) (Figure 2). The third targeted a variable
9-mer epitope (Nef19-27), which differed between the two
T/F viruses at 2 aa residues at positions 25 and 26.
Escape from T cell responses by virus recombination
The CD8+ T cell response that targeted the variable
Nef68-76 epitope recognized the major T/F epitope with
greater magnitude (>10-fold), higher functional avidity
(Figure 4A and B), and an increased proportion of reactive
cells producing 3 or more cytokines when compared with
the minor virus epitope (Additional file 3: Figure S3).
Within 50aa upstream of the Nef68-76 reactive epitope,
a second Nef specific T cell response, Nef19-27, also rec-
ognized an epitope that was variable. In contrast to the
Nef68-76 T cell response, the Nef19-27 response detected
the minor virus and not the corresponding major virus
epitope (Figure 4C). The minor virus existed at only
4% at Fiebig I-II and therefore the level of presentationin acute infection in CH078. Ex vivo IFN-γ ELISpots were performed
I). Solid colored lines represent individual T cell responses and are
a virus load (pVL) of CH078 is plotted as a dotted line on each graph.
4× background. All data represent the background subtracted mean
name based on HXB2 aligned amino acid position within individual
pe entropy are listed below the figure. Parentheses around HLA
otif as opposed to experimentally confirmed HLA restriction.
Figure 3 CD8+ T cells targeting shared epitopes escaped via accumulation of variants in the reactive epitope. The epitopes Rev12-20
(A), Pol426-434 (B), Vif73-81 (C), and Gag25-34 (D) were shared between the major and minor T/F viruses and showed escape. The top graph in
each figure represents the changing frequencies of each epitope as measured by SGA sequencing over time. The bottom graph in each figure
represents the absolute magnitude of the T cell responses targeting all tested variants of the epitope, measured using ex vivo IFN-γ ELISpots. Each
figure has a different scale on the Y axis for the bottom graph. Data for the T/F epitope are shown using squares, data relating to the escape
variants tested in T cell assays are shown as triangles, while in the top graph only, other epitope variants (neither T/F nor tested escape variants)
are shown as gray circles (others). Screening corresponds to Fiebig I/II.
Ritchie et al. Retrovirology 2014, 11:69 Page 4 of 10
http://www.retrovirology.com/content/11/1/69of this epitope would have been very low relative to the
corresponding major epitope. By day 35, the minor
Nef19-27 epitope was found in 15% of sequences but
no T cell response was detectable in ex vivo assays. How-
ever, at the next timepoint (day 49) when cells were avail-
able, this T cell response was detected strongly at > 500
SFU/106 cells, suggesting this T cell response emerged be-
tween day 35 and 49.
Given that these Nef-reactive T cell responses each tar-
geted the major and minor T/F viruses in a reciprocal man-
ner, we explored whether HIV-1 could evade these two T
cell responses through recombination. Amino acid vari-
ation between the two T/F viruses was also found in the re-
gion (114aa) surrounding these epitopes (Figure 5),
which allowed us to unequivocally distinguish therecombinants from the T/F viruses and identify recom-
bination breakpoints. No recombination was detected
before day 35 (Additional file 4: Figure S4). At day 35,
2 out of 25 (8%) of sequences were recombinants, and
both of these shared identical breakpoints (Figure 5,
Additional file 4: Figure S4). Recombinants increased to
44% and 65% at days 42 and 49 respectively, with different
breakpoints identified in different sequences (Additional
file 4: Figure S4). From days 35 to 49, a total of 32 se-
quences had a recombination breakpoint between the two
epitopes, and in all cases were found to be carrying the
epitopes least targeted by T cell responses (Figure 5). Five
distinct breakpoints were identified in this population of
32 sequences (Figure 5). This suggests that these viruses
became dually resistant to the Nef-reactive CD8+ T cell
Figure 4 CD8+ T cell responses differentially recognized Nef epitopes in the 2 T/F viruses. The epitopes Nef68-76 (A) and Nef19-27 (C)
varied between the major and minor T/F viruses. T cell responses were measured by ex vivo IFN-γ ELISpots with responses against the major T/F
shown by blue squares and responses against the minor T/F shown as red diamonds. T cell responses to subsequently emerging escape variants
are shown as triangles. To the right of these graphs, the changes in each epitope are shown over time. The EC50 of the Nef68-76 T cell response
targeting the major variant was lower than that of the response targeting the minor variant (B). dps = days post-screening (Fiebig I/II).
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the recombinants were selected because they afforded a
replication advantage under dual T cell selection pressure.
Classical T cell escape of variable epitope occurred
following recombination
As infection progressed, initial, partial escape from the T
cell responses targeting two Nef epitopes through recom-
bination was followed by classic escape, i.e. the emergence
of de novo mutations (not present in either T/F virus and
not derived through recombination) within the targeted
epitopes, conferring complete escape. The R71T change at
position 4 in the Nef68-76 epitope, which was first
detected at day 134 and was present in 100% of SGA
sequences at day 441, abrogated all detectable T cell
recognition (Figure 4A). In the Nef 19–27 epitope, additional
intra-epitope R19K and R21K changes also independently
ablated Tcell recognition (Figure 4C).
Discussion
Two major determinants of virus escape patterns are
immunodominance and epitope entropy (population
level sequence variability) [10,11]. In CH078, the earlyimmunodominant Rev-specific T cell response which
targeted a high entropy epitope escaped within weeks
(Figure 3). Escape in this epitope occurred classically
through the accumulation of non-synonymous mutations
within the epitope. Conversely, the acute CD8+ T cell re-
sponse targeting the Gag TL9 epitope which is very low
entropy did not escape over the study window, despite
subsequently gaining immunodominance. Slow escape in
the TL9 epitope has been described elsewhere [33].
By contrast, the Nef68-76 CD8+ Tcell response, which was
subdominant and targeted a low entropy epitope, both pa-
rameters associated with slow virus escape [10], escaped rap-
idly, within weeks of infection. Here, recombination provided
an accelerated escape in acute HIV-1 infection. The efficiency
of recombination as a rapid mode of escape from T cell
immune pressure in acute HIV-1 infection was highlighted
by selection of recombinants that simultaneously excised two
Nef epitopes located 50aa apart. Five different recombination
patterns were selected within the same short period, strongly
implying that direct selective forces were acting on this region
as opposed to selection occurring elsewhere in the genome
and recombinant strains becoming dominant through linkage
between two epitopes with escape mutations.
Nef19-27 Nef68-76 % of variant
Major T/F MGGKWSKSSIVGWPDVRERIRRTAQAAEGVGAASQDLDKYGALTTSNTAHNNADCAWLQAQEEEEDVGFPVRPQVPLRPMNYKAAFDLSFFLKEKGGLEGLIYSKKRQEILDLW
Minor T/F ---------L--------------PT-------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D----- Major  Minor  Recombinant
d35.3       -----------------------------------------------------------------------K--------T--------------------VH-Q---D----- 80% 12%     8%
d35.4       -----------------------------------------------------------------------K--------T--------------------VH-Q---D-----
d42.2       -------------------------------------N---------------------------------K--------T--------------------VH-Q---D----- 50%     6% 44%
d42.9       -------------------------------------N---------------------------------K--------T--------------------VH-Q---D-----
d42.8       -----------------------------------------------------------------------K--------T--------------------VH-Q---D-----
d42.J       -----------------------------------------------------------------------K--------T--------------------VH-Q---D-----
d42.O       -----------------------------------------------------------------E-----K--------T--------------------VH-Q---D-----
d42.25      ---------------------------------------------------------------G-E-----K--------T--------------------VH-Q---D-----
d42.L       ---------------------------------------------------------------G-E-----K--------T--------------------VH-Q---D-----
d42.18      -----------K--N------------------------------------------VK----G-E-----K--------T--------------------VH-Q---D-----
d42.G       ---------------------------------------------------------VK----G-E-----K--------T--------------------VH-Q---D-----
d42.I       ---------------------------------------------------------VK----G-E-----K--------T-----------......................
d42.6       ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d42.19      ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d42.13      ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d42.29      ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d42.H       ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.2     -----------------------------------------------------------------E-----K--------T--------------------VH-Q---D----- 17% 17%   65%
d49.12    -----------------------------------------------------------------E-----K--------T--------------------VH-Q---D-----
d49.19      -----------------------------------------------------------------E-----K--------T--------------------VH-Q---D-----
d49.25      ---------------------------------------------------------------G-E-----K--------T--------------------VH-Q---D-----
d49.10      ---------------------------------------------------------VK----G-E-----K--------T--------------------VH-Q---D-----
d49.23      ---------------------------------------------------------VK----G-E-----K--------T--------------------VH-Q---D-----
d49.18      ---------------------------------------------------------VK----G-E-----K--------T--------------------VH-Q---D-----
d49.9     ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.13    ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.4     ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.1     ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.24    ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.16    ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.3     ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
d49.21    ---------------------------------------H-----N---R---TW--VK----G-E-----K--------T--------------------VH-Q---D-----
Figure 5 HIV-1 recombination can afford rapid escape from acute CD8+ T cell responses. The first 114 amino acid region of Nef spanning
the two variable T cell epitopes in CH078 were analyzed. The recombination breakpoints between the epitopes are shown. The major and minor
T/F consensus sequences are displayed above the individual sequences. Sequences derived from the major T/F are highlighted in blue and
sequences from the minor T/F are highlighted in yellow, while the regions in which recombination probably occurred are indicated in grey. The
patient ID and days post screening (dps) which corresponded to Fiebig I/II are followed by individual sequence identifiers. The 2 epitopes are
outlined by red boxes. Graphical inserts beneath each epitope indicate the magnitude of T cell responses targeting the major and minor T/F
variant of each epitope (data derived from Figures 4A and C). On the right, the percentage of the recombinant viruses at each timepoint is
shown. Non-recombinant viruses are broken down in the % major or minor virus. Note, at day 35, two 3′ sequences (of 27) with large deletions
were excluded from analysis.
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T cell escape in acute infection are novel. They add to,
but are distinct from, two previous reports that describe
superinfection in the chronic stage of HIV-1 infection.
Those studies described the selection of the superinfect-
ing strain because it contained mutations that conferred
escape from circulating T cell responses [29,34]. In one
of these studies, recombination was detected in a patient
two months after the superinfection event, and was asso-
ciated with T cell pressure [29]. Here, our more detailed
sampling clearly shows that primary HIV-1 specific T
cell responses can select recombination between distinct
T/F viruses even more rapidly, within weeks of infection
when pVL is stabilizing prior to the establishment of set-
point. These observations provide empirical evidence of
a mechanism beyond stochastic events to explain the
emergence of recombination reported in acute infection[12,14,15,17]. A striking feature of the results presented
here are the five independent recombinations observed
in a very short time period and the fact that two separate
T cell responses, neither immunodominant, combined to
select the recombinations.
Very interestingly, as infection progressed the early re-
combination mediated escape in the Nef epitopes was
followed by the emergence of non-synonymous mutations
within the targeted epitopes that themselves more strongly
ablated CD8 T cell recognition. This is consistent with re-
combination offering not only an alternate route of escape
but in some cases more rapid escape.
Our observations are also consistent with others
[35,36], that show T cell escape is a dynamic process. In
addition to the ongoing emergence of HIV-1 variants
through either recombination or mutation, we also ob-
served changing recognition of T cell escape variants
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Text). This is best explained by the emergence of
discrete circulating T cell clonotypes that differentially
recognized epitopes as HIV-1 infection progressed [33].
These data underscore the complexity of interpreting T
cell selection pressure in chronic HIV-1 infection.
Although it seems likely that the selection of recombi-
nants in some patients may have negative outcomes for
the host, this did not occur in this patient, at least in the
study window observed. Other host responses, including
the subject’s more dominant T cell responses which exhib-
ited consistent oligofunctionality, could have contributed
to the virus control observed; particularly as this subject
expressed the HLA B*81 allele which is overrepresented in
viremic controllers [37]. Other viremic factors, variation
in Nef-mediated immune evasion [38,39] or Gag-Protease
replicative capacity [40] could have resulted in emergence
of less fit and or less pathogenic viruses resulting in the
lower setpoint. Given the number of variables in this, a
single patient study, we cannot draw firm conclusions re-
garding the HIV-1 control observed.
Conclusions
This in depth case study of a patient infected with two T/F
HIV-1 viruses has demonstrated that the appearance of
recombinants known to occur during acute infection
[12,14,15,17] can be driven by the selective action of CD8+
T cell responses.
These observations have clinical implications. Whilst
we show that recombination mediated escape can occur
within weeks of infection, the generation of escape mu-
tants will be generally slower in regions of sequence
conservation. Vaccine-induced T cell responses that
dominantly target conserved regions of HIV-1 will
therefore also be less subject to rapid escape by recom-
bination suggesting a conserved immunogen design for
prophylactic T cell vaccines could also retain benefit in
individuals infected with > 1 HIV-1 T/F virus. Func-
tional cure of HIV-1 is an emerging field with a role for
HIV-1 specific CD8 T cells to detect and inhibit HIV-1
reservoirs recently highlighted [41]. Our observations
suggest that following reactivation of the HIV-1 reser-
voir, recombination between proviruses, even in individ-
uals who received very early antiretroviral therapy,
could mediate very rapid escape from T cell responses.
Methods
Study subject
CHAVI patient 078 is a black South African male aged
22 at the time of screening. Transmission occurred via
heterosexual sex from a known HIV-1+ patient. The sub-
ject remained antiretroviral naive over the subsequent
study period of 442 days. At screening, approximately
22 days post transmission, samples were collected forviral identification and serology only. Twenty-one days
post-screening, the patient was enrolled into the acute
infection arm of the Center for HIV/AIDs Vaccine Im-
munology (CHAVI) 001 study. At enrolment and all
subsequent visits, blood was drawn, PBMCs isolated,
and these cells used for subsequent T cell studies.
Plasma and sera were also isolated for viral sequencing
at these visits.
Amplification of near full-length viral genome by SGA
Viral RNA was extracted from longitudinal plasma sam-
ples using the PureLink Viral RNA/DNA Mini Kit (Invi-
trogen, Carlsbad, CA). cDNA was synthesized using the
SuperScript III reverse transcriptase (Invitrogen, Carlsbad,
CA) with the primers 07Rev8 5′- CCTARTGGGATG
TGTACTTCTGAACTT-3′ (nt5193-5219 in HXB2) for
the 5′ half genome, or primer 1.R3.B3R 5′- ACTACTT
GAAGCACTCAAGGCAAGCTTTATTG-3′ (nt9611-9
642) for the 3′ half genome. Single genome amplifica-
tion (SGA) was performed to obtain the 5′ half, 3′ half or
near full-length HIV-1 genome as described previously
[13,42]. For the 5′ half genome amplification, the first
round PCR was carried out using the primers 1.U5.B1F
5′-CCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTG
T-3′ (nt538-571) and 07Rev8 5′-CCTARTGGGATGTGT
ACTTCTGAACTT-3′ (nt5193-5219), and the second
round PCR with primers Upper1A 5′-AGTGGCGCCCGA
ACAGG-3′ (nt634-650) and Rev11 5′-ATCATCACCTGC-
CATCTGTTTTCCAT-3′ (nt5041-5066). To amplify the 3′
half genome, the first round PCR was performed using the
primers 07For7 5′-CAAATTAYAAAAATTCAAAATTT
TCGGGTTTATTACAG-3′ (nt 4875–4912) and 2.R3.B6R
5′-TGAAGCACTCAAGGCAAGCTTTATTGAGGC-3′
(nt9636-9607), and the second round PCR with primers
VIF1 5′-GGGTTTATTACAGGGACAGCAGAG-3′ (nt4
900-4923) and Low2c 5′-TGAGGCTTAAGCAGTGGG
TTCC-3′ (nt9591-9612).Sequence analysis
The SGA amplicons were directly sequenced by the cycle
sequencing and dye terminator methods on an ABI 3730xl
genetic analyzer (Applied Biosystems, Foster City, CA). In-
dividual sequences were assembled and edited using
Sequencher 4.7 (Gene Codes, Ann Arbor, MI). The se-
quences were aligned using CLUSTAL W [43] and the
manual adjustment for optimal alignment was performed
using Seaview. The Neighbor-joining (NJ) tree was con-
structed using the Kimura 2-parameter model. The high-
lighter plot was generated using the Highlighter tool at the
Los Alamos HIV sequence database (http://www.hiv.lanl.
gov/content/sequence/HIGHLIGHT/highlighter_top.html).
Genbank accession numbers: 3′ sequences KC149035-
149139, 5′ sequences KC148775-149034.
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All sequences from different time points were compared
to the parental T/F sequences. Recombination break-
points were identified by RDP3 followed by manually in-
spection of the Highlighter plot. The aligned sequences
were analyzed for recombination signals using BOOT-
SCAN, GENECONV, MAXCHI, CHIMAERA, SISCAN
and 3SEQ in the program RDP3 with a window size of
20 nucleosides [44]. The T/F sequences were used as the
parental sequences.T cell response analysis
IFN-γ ELISpot mapping, Shannon entropy calculations [45]
and time to T cell escape were performed as previously de-
scribed [10]. For mapping, the entire proteome of both T/F
viruses were tested using PBMCs from days 28 and 187,
while responses against both NEF proteomes were add-
itionally tested for at days 42 and 105. To investigate
whether ‘novel’ T cell responses were induced in response
to viral diversification, variant peptides that matched non-
synonymous ‘stripes’ that emerged over the course of the
study window were tested. No de novo T cell responses
were detected.
Once all optimal epitopes had been identified, these
were tested at 1 μM concentrations as outlined across
multiple visits using ex vivo IFN-γ ELISpots and flow cy-
tometry. Avidity of responses was tested at some time-
points using peptide dilutions. Peptides are identified by
alignment to HXB2 proteins.Flow cytometry
Following thawing and O/N resting, PBMCs were stimu-
lated with peptide or control (0.45% DMSO) for 6 hrs in
the presence of Costim™ (BD Biosciences) plus Brefeldin
A and Monensin. Anti-CD107a fluorochrome-labelled
antibody was also added to assay for degranulation. Cells
were then washed with PBS and incubated with LIVE/
DEAD Aqua viability dye (Invitrogen Life Technologies)
followed by fluorochrome labelled antibodies against
CD4, CD8, CD19, CD45RO and CD27. Cells were fixed
and permeabilised using Cytofix™ prior to staining with
fluorochrome-labelled antibodies against CD3, IFN-γ,
TNF-α and IL-2. Flow cytometry was performed on BD
LSRII and data was analysed using FlowJo (Tree Star
Inc.) using the following gating strategy lymphocytes/sin-
glets/alive/CD19-CD3+/CD4-CD8+/exclusion of CD27 +
CD45RO- cells. Polyfunctionality was analysed using Pes-
tle and SPICE software from Dr Mario Roederer, NIH.
Data shown is background subtracted and a positive re-
sponses defined the mean plus two standard deviations of
mock-stimulated response measured across all timepoints
(n = 7) tested.Ethics Statement
CHAVI 078 gave full, written consent to enrol into the
acute infection arm of CHAVI 001. Experiments were
approved by the Prevention Sciences Review Committee,
Division of Acquired Immunodeficiency Syndrome and
by the Oxford Tropical Research Ethics Committee.Additional files
Additional file 1: Figure S1. Highlighter analysis of sequential half
genome sequences from subject CH078. 5′ and 3′ half genomes
overlapping by 118bp were amplified by SGA from sequential plasma
viral RNA. The Highlighter plots denote the location of nucleotide
substitutions compared to the sequence representing the inferred major
T/F virus. The days post screening (Fiebig I/II) are indicated at the right of
the plot. Nucleotide substitutions and gaps are color-coded. Gene
locations are indicated beneath each highlighter plot. For the 5′ half of
the genome, the presumed minor T/F virus is noted in the 28 days
post-screening data and for the 3′ half of the genome, the minor T/F
virus noted in the 0 days post-screening data.
Additional file 2: Figure S2. T cell responses were CD8+ restricted and
primarily of the CD45RO+CD27+ central memory phenotype. Cumulative
data on the expression of CD45RO and CD27 by IFN-γ producing CD8+ T
cells from intracellular cytokine flow cytometry for each positive peptide
response (n=21) observed over study visits between days 21 and 187
from screening/Fiebig I-II. Data are grouped to show T cell phenotypes in
response to stimulation with epitopes found in either the major or minor
T/F viruses as well as subsequent escape variants. The percentage of
central memory (CD27+CD45RO+), effector memory (CD27-CD45RO+),
and terminal effector (CD27-CD45RO-) cells within the IFN-γ+ CD8+ T cell
population are shown. Bars represent the mean ± 1 standard deviation
for each memory population.
Additional file 3: Figure S3. CD8+ T cells express IFN-γ, TNF-α and the
degranulation marker CD107a in response to both the major and minor
variants of Nef68-76. Intracellular cytokines and CD107a expression by
CH078 PBMC were assayed by flow cytometry after 6 hours of stimulation
with 2μg/ml peptide representing either the major (FPVRPQVPL) or minor
(FPVKPQVPL) epitope variants of Nef68-76. A) Single function analysis.
Percentage of CD8 memory T cells expressing CD107a (red), IFN-γ
(purple) and TNF-α (green) in response to the major (solid line) or minor
(dotted line) epitope variants at days 49, 77 and 134 post-screening
(Fiebig I/II). B) The proportions of the specific CD8+ memory T cell
response accounted for by cells producing all possible combinations of
IFNγ, TNFα, IL-2 and CD107a. Colored arcs indicate expression of each
individual marker and the shaded sectors show the proportion of cells
expressing each marker combination.
Additional file 4: Figure S4. Highlighter recombination plot of partial
nef gene sequence. The first 342 bp of the nef gene sequence containing
both Nef T cell epitopes were used to detect recombination events. The
major and minor T/F viral sequences are shown in blue and red lines at
the top, respectively. The major and minor T/F virus signature nucleotides
are indicated as blue and red ticks, respectively. The nucleotides that
differ from both T/F viruses are indicated as black ticks. The Nef T cell
epitopes are outlined in green box. The days post-screening (Fiebig I/II)
are indicated at the right of the plot.
Additional file 5: Supplementary Text. Maturation of classic virus
escape. As previously described, the emergence of virus variants within T
cell epitopes is not static and changes over time [9,10,35]. Given our
access to longitudinal samples, we examined how the more common
epitope variants that emerged at different stages following infection
impacted T cell recognition in the shared epitopes. Several patterns were
observed. In the early immunodominant Rev12-20 epitope, the most
effective R17K escape remained dominant in the virus population and
the less effective K20R variant disappeared by day 77 (Figure 3A). In 2
epitopes (Gag25-34, Nef68-76), maturation of virus escape was observed
with different escape variants dominant at earlier and later timepoints
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(Figures 3D and 4A). These examples suggest that under ongoing T cell
selection, HIV-1 ultimately selected the most effective virus escape.
Interestingly, in a fourth epitope (Vif73-81), the early A78D mutation
ablated the T cell response much more strongly than the P75T mutation
which arose later in infection. This hierarchy of recognition changed
with time. At day 266, the P75T mutation ablated T cell recognition far
more effectively than the A78D mutation (Figure 3C). The changing
recognition by T cells of escape variants over time, suggests the
emergence of discrete circulating T cell clonotypes that differentially
recognize these epitopes, recently described in chronic HIV-1 infection
in [33]. Therefore, not only does HIV-1 evolve in response to T cell
responses, but T cell responses themselves also adapt in response to
virus escape. These data underscore the complexity of interpreting T cell
selection pressure in chronic HIV-1 infection.
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